Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8681-8689

  Neeb, Antje ^a   Hefele, Simon ^b   Bormann, Stefanie ^a,f   Parson, Walther ^c,d   Adams, Fabian ^b   Wolf, Philipp ^b   Miernik, Arkadiusz ^b   Schoenthaler, Martin ^b   Kroenig, Malte ^b   Wilhelm, Konrad ^b   Schultze Seemann, Wolfgang ^b   Nestel, Sigrun ^e   Schaefer, Georg ^c   Bu, Huajie ^c   Klocker, Helmut ^c   Nazarenko, Irina ^b   Cato, Andrew C B ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anterior gradient 2 gene; Exosomes; Prostate cancer diagnosis; Splice variants; Urinary biomarkers

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; BIOLOGICAL MARKER; MEMBRANE PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; AGR2 PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MESSENGER RNA; PROTEIN; TUMOR MARKER;

ADULT; AGR2 GENE; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EXOSOME; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MALE; MARKER GENE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; URINALYSIS; AGED; AREA UNDER THE CURVE; BIOPSY; BLOOD; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; TUMOR CELL LINE; URINE;

AGED; ALTERNATIVE SPLICING; AREA UNDER CURVE; BIOPSY; CELL LINE, TUMOR; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEINS; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84907997100     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2365     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou, Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-916.
3. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001; 344: 1373-1377.
4. Nadler RB, Humphrey PA. Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995; 154: 407-413.
5. Pascal LE, Vêncio RZ, Page LS, Liebeskind ES, Shadle CP, Troisch P, Marzolf B, True LD, Hood LE, Liu AY. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes. BMC Cancer. 2009; 9: 452.
6. Aberger F, Weidinger G, Grunz, H, Richter K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev. 1998; 72: 115-130.
7. Brychtova V, Vojtesek B, Hrstka R. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 2011; 304: 1-7.
8. Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun. 1998; 251: 111-116.
9. Innes HE, Liu D, Barraclough R, Davies MP, ÓNeill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer. 2006; 94: 1057-1065.
10. Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel, M et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol. 2005; 205: 359-376.
11. Bu H, Bormann S, Schäfer G, Horninger W, Massoner P, Neeb A, Lakshmanan V, Maddalo D, Nestl A, Sültmann H, Cato AC, Klocker H. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate. 2011; 71: 575-587.
12. Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M, Kim SR, Bagryanova L. et al. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol. 2013; 26: 849-859.
13. Fritzsche FR, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G. Expression of AGR2 in non small cell lung cancer. Histol Histopathol. 2007; 22: 703-708.
14. Dumartin L, Whiteman HJ, Weeks ME, Hariharan D, Dmitrovic B, Iacobuzio-Donahue CA, Brentnall TA, Bronner MP, Feakins RM, Timms JF, Brennan C, Lemoine NR, Crnogorac-Jurcevic T. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 2011; 71: 7091-7102.
15. Vivekanandan P, Micchelli ST, Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol. 2009; 40: 293-299.
16. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10: 1470-1476.
17. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010; 24: 2343-2364.
18. Zheng W, Rosenstiel P, Huse K, Sina C, Valentonyte R, Mah N, Zeitlmann L, Grosse J, Ruf N, Nürnberg P, Costello CM, Onnie C, Mathew C. et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes. Immun. 2006; 7: 11-18.
19. Bobrie A, Colombo M, Raposo G, Théry C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011; 12: 1659-1668.
20. Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R, Deep G. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. 2013. doi: 10.1002/mc.22124. [Epub ahead of print]
21. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal Cellular Biochem. 2004; 91: 528-539.
22. De Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. DD3 PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002; 62: 2695-2698.
23. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006; 8: 885-888.
24. Marks LS, Fradet Y, Deras IL, Blasé A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007; 69: 532-535.
25. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011; 71: 489-497.
26. Chevet E, Fessart D, Delom F, Mulot A, Vojtesek B, Hrstka R, Murray E, Gray T, Hupp T. Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene. 2013; 32: 2499-509.
27. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Brit J Cancer. 2009; 100: 1603-1607.
28. Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA. Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes. J Urol. 2014; 191:1132-1138.
29. Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schäfer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008; 101: 809-816.
30. Pressinotti, NC, Klocker H, Schäfer G, Luu VD, Ruschhaupt M, Kuner R, Steiner E, Poustka A, Bartsch G, Sültmann H. Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low-and high-risk prostate cancer. Mol Cancer. 2009; 8: 130.
31. Wolf P, Freudenberg N, Bühler P, Alt K, Schultze-Seemann W, Wetterauer U, Elsässer-Beile U. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010; 70: 562-569.